A Phase 1 interventional study of Follitropin alfa (Primapur) and Follitropin alfa (Gonal-F) in Area Under Curve, Pharmacokinetics and Absorption, sponsored by IVFarma LLC. Completed at 1 site in Russian Federation. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-13.
Sponsored by IVFarma LLC · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the current phase I study was to establish bioequivalence, safety, and tolerance of single 300 IU subcutaneous dose of follitropin alfa biosimilar (Primapur) in comparison to that of reference follitropin alfa preparation (Gonal-F) in healthy young female volunteers.
A Phase I, prospective, randomized, open-label, crossover, 2-period, two treatment, clinical study in healthy female volunteers.
Objectives of the study:
IVFarma LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
Drug: Follitropin alfa (Primapur) · Drug: Follitropin alfa (Gonal-F)
Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
Drug: Follitropin alfa (Primapur) · Drug: Follitropin alfa (Gonal-F)
During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences: Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F. Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Also known as: Follitropin alpha, Follitropin
During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences: Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F. Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.
Also known as: Follitropin alpha, Follitropin
Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))
Area under curve (AUC), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose. Blood samples to study the pharmacokinetics are to be collected via a venous catheter, which is placed by means of vein puncture before any injection of r-hFSH. Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.
Time frame: 0-192 hours
Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)
Maximum serum concentration (Cmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
Time frame: 0-192 hours
Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)
Time to reach a maximum serum concentration (Tmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
Time frame: 0-192 hours
Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)
Terminal half-life (T1/2), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
Time frame: 0-192 hours
Elimination Rate Constant (Kel)
Elimination rate constant (Kel): Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
Time frame: 0-192 hours
Duration of participation was about 73 days: screening period (up to 7 days), preparation period (up to 28 days), the 1st period (9 days), the 2nd period (9 days), and the follow-up period (28 days starting from the first day of the 2nd period). The wash-out period is 10 days.
| Milestone | Sequence A: Primapur - Gonal-F | Sequence B: Gonal-F - Primapur |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| Milestone | Sequence A: Primapur - Gonal-F | Sequence B: Gonal-F - Primapur |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
Area under curve (AUC), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose. Blood samples to study the pharmacokinetics are to be collected via a venous catheter, which is placed by means of vein puncture before any injection of r-hFSH. Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.
| mIU*h/ml | Primapur | Gonal-F |
|---|---|---|
| Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192)) | 1202.85 ± 466.28 | 1241.01 ± 418.61 |
Maximum serum concentration (Cmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
| mIU/ml | Primapur | Gonal-F |
|---|---|---|
| Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax) | 14.32 ± 4.72 | 16.00 ± 4.88 |
Time to reach a maximum serum concentration (Tmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
| hours | Primapur | Gonal-F |
|---|---|---|
| Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax) | 18.70 ± 5.77 | 19.22 ± 4.93 |
Terminal half-life (T1/2), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
| hours | Primapur | Gonal-F |
|---|---|---|
| Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2) | 70.78 ± 32.54 | 71.71 ± 33.47 |
Elimination rate constant (Kel): Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.
| 1/h | Primapur | Gonal-F |
|---|---|---|
| Elimination Rate Constant (Kel) | 0.01 ± 0.003 | 0.01 ± 0.006 |
Collected over From the study day 1 to day 56.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primapur | 0/24 (0%) | 0/24 (0%) | 11/24 (45.8%) |
| Gonal-F | 0/24 (0%) | 0/24 (0%) | 10/24 (41.7%) |
| Event | Primapur | Gonal-F |
|---|---|---|
| Laboratory investigationsInvestigations | 8/24 | 8/24 |
| HeadacheNervous system disorders | 2/24 | 3/24 |
| NauseaGastrointestinal disorders | 1/24 | 1/24 |
| VomitingGastrointestinal disorders | 0/24 | 1/24 |
Women aged 18 to 40 years; body mass index (BMI) of 18.5 to 30 kg/m2
| Age, Categorical(Participants) | Sequence A: Primapur - Gonal-F | Sequence B: Gonal-F - Primapur | Total |
|---|---|---|---|
| Periods 1 and 2 — <=18 years | 0 | 0 | 0 |
| Periods 1 and 2 — Between 18 and 65 years | 12 | 12 | 24 |
| Periods 1 and 2 — >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Sequence A: Primapur - Gonal-F | Sequence B: Gonal-F - Primapur | Total |
|---|---|---|---|
| Mean | 29.92 ± 4.27 | 26.58 ± 3.12 | 28.25 ± 4.04 |
| Sex: Female, Male(Participants) | Sequence A: Primapur - Gonal-F | Sequence B: Gonal-F - Primapur | Total |
|---|---|---|---|
| Female | 12 | 12 | 24 |
| Male | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Sequence A: Primapur - Gonal-F | Sequence B: Gonal-F - Primapur | Total |
|---|---|---|---|
| Russia | 12 | 12 | 24 |
| Body mass index (BMI)(kg per m2) | Sequence A: Primapur - Gonal-F | Sequence B: Gonal-F - Primapur | Total |
|---|---|---|---|
| Mean | 23.41 ± 3.53 | 22.41 ± 2.80 | 22.91 ± 3.16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2015 to primary completion in May 2016, 6 months.
Results were first posted in Aug 2019, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa